Fri, 17 Sep 1999 13:00:00 GMT https://oxfordglobal.com/nextgen-biomed/resources/lonza-and-vertex-pen-long-term-supply-deal-for-casgevy Lonza will provide scientific, regulatory and manufacturing capabilities to Vertex, as well as use of their global manufacturing network. Mon, 01 Oct 2024 13:00:00 GMT nextgen biomed https://oxfordglobal.com/precision-medicine/resources/ghr-foundation-commits-15m-to-c2n-diagnostics-for-tau-tangle-pathology-test-for-diagnosing-staging-alzheimers-disease GHR’s total investment in C2N has now broken $50 million since 2020. Mon, 01 Oct 2024 13:00:00 GMT precision medicine https://oxfordglobal.com/nextgen-biomed/resources/new-research-into-newborn-gut-microbiome-identifies-three-pioneer-bacteria-for-babies-microbiota-development The researchers analysed high-resolution genomic information from over 1,200 babies and identified three pioneer bacteria that drive the development of the gut microbiota. Wed, 11 Sep 2024 13:00:00 GMT immuno https://oxfordglobal.com/nextgen-biomed/resources/insilico-medicine-and-inimmune-pen-collaboration-for-ai-powered-immunotherapy-discovery The two biotechs are working together to overcome specific hurdles in the immunotherapy drug discovery process. Tue, 10 Sep 2024 13:00:00 GMT immuno https://oxfordglobal.com/precision-medicine/resources/national-university-of-singapore-unveil-novel-single-cell-rna-analysis-technique The novel technique effectively denoises scRNA-seq data by fitting a low-dimensional manifold in the high-dimensional space. Tue, 10 Sep 2024 13:00:00 GMT omics https://oxfordglobal.com/precision-medicine/resources/study-analyses-predictive-biomarkers-for-covid-19-icu-patient-mortality The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU. Fri, 06 Sep 2024 13:00:00 GMT biomarkers https://oxfordglobal.com/precision-medicine/resources/ai-analysis-of-patient-serum-presents-promising-new-lyme-disease-diagnosis-tool The AI-enabled immunological approach aims to bring accurate diagnoses faster and sooner after potential infection. Mon, 02 Sep 2024 13:00:00 GMT omics http://www.oxfordglobal.com/nextgen-biomed/resources/a-new-cancer-killing-bispecific-antibody-working-toward-the-clinic-in-2022 The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours Mon, 17 Jan 2022 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/diabetologys-oral-insulin-has-success-in-iib-clinical-trial Strides made in a landmark phase IIb oral insulin clinical trial. Mon, 03 Jan 2022 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/fda-approves-takedas-subcutaneous-ulcerative-colitis-mab The company can now sell their biologic for ulcerative colitis in a subcutaneous form on the US market. Fri, 29 Sep 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/how-do-regulatory-considerations-impact-the-clinical-development-of-oligonucleotide-therapies What are the regulatory considerations that need to be made in the clinic for oligonucleotide therapies? What's the existing guidance for this emerging modality? Tue, 26 Sep 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/multispecific-antibody-development-interview-with-yue-liu-president-and-founder-of-ab-therapeutics Discussing using a computational drug discovery platform for the development of multispecific antibody therapeutics. Fri, 27 Oct 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/introducing-the-development-and-clinical-landscape-of-bi-and-multispecific-antibodies While bispecific antibodies target two specific entities, multispecific antibodies can target more than two. The use of these engineered antibodies offers the potential for enhanced therapeutic strategies by simultaneously addressing multiple aspects of a disease. Thu, 16 Nov 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/interview-with-andrew-brown-head-of-process-development-sciences-at-lonza Andrew Brown, Head of Process Development Sciences at Lonza, talks about Lonza's approach to process development. Mon, 27 Mar 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/sustainable-medicines-partnership-a-pan-stakeholder-action-collaborative A program to reduce the waste of medicines and waste from medicines, centred around six pillars for sustainable pharma. Tue, 16 May 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/strengthening-preparedness-for-the-next-pandemic-interview-with-ramin-sabet-azad-cmc-lead-cepi How do we prepare for the next pandemic? Thu, 26 Oct 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/the-power-of-collaboration-how-the-sustainable-healthcare-coalition-measures-the-impact-of-sustainable-healthcare The Sustainable Healthcare Coalition (SHC) emphasises the importance of collaboration with industry to address climate change in healthcare. Wed, 24 May 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/vaccine-production-for-better-global-access How were the COVID-19 vaccines developed so fast? And why were some countries left behind? Wed, 11 Oct 2023 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/new-peptide-with-hope-of-treating-triple-negative-breast-cancer The preclinical peptide could unlock much needed treatment options for patients with triple-negative breast cancer. Fri, 26 Jan 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/mechanochemical-synthesis-as-a-solvent-free-peptide-synthesis-method Mechanochemical synthesis could unlock new pathways for obtaining peptides in a sustainable and ecologically friendly way. Tue, 20 Feb 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/recombinant-vs-chemical-peptide-synthesis-a-question-of-sustainability Recombinant and chemical peptide synthesis methods both have use cases in modern peptide production. Today the industry is looking to sustainable approaches to both. Wed, 28 Feb 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/innovation-at-the-crossroads-oligonucleotide-therapeutics-and-the-evolution-of-drug-design Can oligonucleotide therapeutics shape the future of healthcare? We journey through AI frontiers, sustainable synthesis, and regulatory challenges. Mon, 11 Mar 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/japanese-team-successfully-skip-abnormal-gene-in-vitro-with-antisense-oligonucleotide-for-bpan Rare disease BPAN currently has no treatment options, this new research investigates whether antisense oligonucleotide therapies could be the answer to address this unmet need. Fri, 22 Mar 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/merus-preclinical-bispecific-zeno-demonstrates-efficacy-in-cancer-models Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling. Wed, 10 Apr 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/worlds-first-ind-approval-for-epstein-barr-mrna-cancer-vaccine Epstein-Barr virus has been highly linked to over ten forms of cancer. This wide range of malignant implications means an expanded variety of target indications for the vaccine. Tue, 14 May 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/h5n1-bird-flu-outbreaks-effect-on-vaccines H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines. Tue, 28 May 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/looking-back-on-the-2002-nobel-prize-for-chemistry-mass-spectrometry-for-the-analysis-of-proteins 2002's Nobel Prize for Chemistry recognised the translation of mass spectrometry to large molecules which has been instrumental in unlocking the proteome toward new therapies. Sun, 23 Jun 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/2002-nobel-prize-for-chemistry-kurt-wüthrich-using-nmr-to-determine-the-3d-structure-of-proteins Kurt Wüthrich, joint winner of the 2002 Nobel Prize for Chemistry, contributed to the use of NMR to discover the 3D structure of proteins using sequential assignment and mathematical techniques. Sun, 30 Jun 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/gsk-buys-curevacs-mrna-vaccine-business-providing-welcome-cash-injection CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines. Wed, 03 Jul 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/fda-fast-track-adc-for-patients-with-triple-negative-breast-cancer The fast track designation means that the clinical development and regulatory milestones of the drug candidate are likely to progress much faster. Mon, 15 Jul 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/rsc-emerging-technologies-award-goes-to-solid-phase-peptide-synthesis-group The novel peptide synthesis protocol allows the synthesis of multiple peptide fragments on a single bead. Tue, 06 Aug 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/nextgen-biomed/resources/absci-to-collaborate-with-the-memorial-sloan-kettering-cancer-center-to-develop-biologics-using-ai The two organisations will work side by side on up to six programmes which will develop new cancer drug candidates using AI. Tue, 20 Aug 2024 13:00:00 GMT biologics http://www.oxfordglobal.com/precision-medicine/resources/overcoming-the-regulatory-challenges-of-digital-health-technologies Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints. Wed, 19 Jan 2022 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/the-patient-focused-paradigm-shift-that-could-revolutionise-clinical-trials Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials. Mon, 21 Feb 2022 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/machine-learning-metabolomics-approach-used-to-diagnose-ovarian-cancer Researchers have used an artificial intelligence model to analyse the metabolites of patients with or without ovarian cancer and have reported shocking accuracy of diagnosis. Wed, 31 Jan 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/investigating-biases-in-diagnostics-and-biomarkers-three-case-studies In the quest to improve diagnostics, new technologies are key, but so is overcoming entrenched bias. Tue, 06 Feb 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/early-diagnostic-blood-biomarker-for-dementia-identified-using-proteomics The team hopes to develop the biomarker into a test that could be used in GP surgeries. Early prediction of dementia could be a gamechanger for new Alzheimer's therapies. Tue, 13 Feb 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/speech-analysis-tool-for-the-early-detection-of-alzheimers-handed-to-linus-health-in-acquisition Aural Analysis's Speech Vitals and Linus Health's expansion into linguistic analysis herald a promising era in early detection and treatment. Thu, 14 Mar 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/new-mnd-early-diagnostic-test-a-game-changer-for-research-on-the-disease Detecting the aggregation of TDP-43 spells a new diagnostic tool for MND. Wed, 10 Apr 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/blood-test-for-alzheimers-granted-breakthrough-device-status-by-fda A blood test for the phosphorylated protein pTau-217 could be a critical step towards early diagnosis and screening of Alzheimer's disease. Thu, 18 Apr 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/new-zika-specific-synthetic-biomarker-can-differentiate-from-dengue-virus A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease. Mon, 13 May 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/hope-for-new-prognostic-biomarkers-therapeutic-options-from-tumour-metabolism-targeting-breast-cancer-study Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers. Mon, 27 May 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/zero-precision-medicine-programme-reports-outstanding-efficacy-in-high-risk-paediatric-cancers The first-of-its-kind trial presents a positive outlook for cancer types with historically poor survival rates. Tue, 11 Jun 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/feinstein-institutes-links-blood-biomarkers-to-psychosis-in-alzheimers-patients The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis. Wed, 26 Jun 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/life-science-players-join-23m-european-project-for-precision-medicine-preciseu The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products. Mon, 08 Jul 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/blood-biomarker-signals-increased-risk-of-alzheimers-mnd-after-multiple-rugby-concussions Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development. Tue, 23 Jul 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/proteomic-analysis-of-serum-extracellular-vesicles-reveals-potential-biomarkers-for-neuroblastoma The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma. Wed, 21 Aug 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/group-identify-prognostic-biomarker-for-sclc-and-treatment-using-chemotherapy SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy. Tue, 27 Aug 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/precision-medicine/resources/study-analyses-predictive-biomarkers-for-covid-19-icu-patient-mortality The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU. Fri, 06 Sep 2024 13:00:00 GMT biomarkers http://www.oxfordglobal.com/nextgen-biomed/resources/tackling-tumours-in-vitro-with-3d-cell-cultures Raymond R. Mattingly explains the applications of 3D cell culturing at Oxford Global's 3D Cell Culture Symposium. Sun, 24 Apr 2022 13:00:00 GMT cell http://www.oxfordglobal.com/nextgen-biomed/resources/three-studies-in-3d-stem-cell-culture Dr Darius Widera shows us three case studies on 3D stem cell cultivation using fibrin, nanofibrillar cellulose, and hybrid scaffolds Fri, 28 Jan 2022 13:00:00 GMT cell http://www.oxfordglobal.com/nextgen-biomed/resources/curing-hiv-with-cell-and-gene-therapy It is now possible to live a long and near normal life with HIV, but what is the likelihood of a permanent cure? Wed, 24 Jan 2024 13:00:00 GMT cell http://www.oxfordglobal.com/discovery-development/resources/how-merck-kgaa-is-using-artificial-intelligence-for-fast-and-reliable-drug-discovery There are innumerable possible compounds in Merck KGaA's virtual library, so finding drug candidates is only possible with the help of computational methods. Mon, 17 Jan 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/artificial-intelligence-for-drug-design-and-discovery Artificial intelligence and machine learning could be an invention comparable to electricity, so what does the future hold for its use in drug discovery? Wed, 16 Mar 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/lantern-pharma-offers-ai-platform-for-adc-discovery-with-bielefeld-university Lantern will use their artificial intelligence (AI) platform, RADR, to accelerate the development of ADC candidates from discovery to clinical trials within a timeframe of approximately two years. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/organ-on-a-chip-market-will-grow-at-21-3-cagr-predicts-roots-analysis-in-2022-2035-forecast The organ modelling technology is making a splash in Roots Analysis market predictions, with recent waves of research grants and patents. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/alphafold-and-drug-design-has-ai-solved-biologys-grand-challenge Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry at Biogen, leads a discussion group on what the revolutionary machine learning technology means for drug design. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/improved-insight-on-methylphenidate-mechanism-of-action A better understanding of ADHD drug methylphenidate's mechanism of action has been revealed by a study published in the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/getting-protacs-into-the-clinic-the-challenges Oxford Global's protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/examining-target-identification-and-validation-in-drug-discovery Target identification and validation forms the backbone of efforts to discover new drugs. Our expert panel discussed challenges and solutions in this field to drive safety and efficacy. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/merck-kgaa-on-training-a-data-capable-workforce Dr Boris Adryan, Digital & Data Capability Building Lead at Merck Healthcare KGaA, teaches the company's workforce the importance of data. Thu, 21 Apr 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/protacs-exciting-opportunities-to-explore-new-biology A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs. Fri, 13 May 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/the-bioavailability-of-oral-protac-molecules-for-er-breast-cancer Thomas Hayhow, Associate Principal Scientist at AstraZeneca presents his company's efforts in delivering PROTACs orally. Wed, 25 May 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/target-identification-navigating-the-intricate-environment-of-human-biology Balancing novelty and validity, the role of probability in target identification, and discussing the role of the genetic links to disease indications. Tue, 07 Jun 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-andrew-robertson-vice-president-head-of-global-regulatory-policy-and-innovation-at-takeda Andrew Robertson, Vice President, Head of Global Regulatory Policy and Innovation at Takeda, talks about working with regulators and the current regulatory paradigm. Thu, 09 Jun 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/challenges-in-translational-approaches-and-biomarkers-in-neurodegeneration Identifying disease targets, understanding complex biology, and developing effective technologies for target engagement. Mon, 13 Jun 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/target-identification-phenotypic-and-cell-based-screening Oxford Global's discussion group brings together specialists in target identification, phenotypic, and cell-based screening Wed, 13 Jul 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/fda-can-deem-animal-modelling-of-drugs-no-longer-necessary For the first time since 1938, the FDA will no longer require animal modelling for drugs to enter clinical trials after a new Act is passed. Thu, 21 Jul 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/up-and-coming-investigations-in-drug-discovery-and-development-neuroscience-and-ai Drug discovery experts join Oxford Global's Neuroscience Drug Discovery and Development discussion group. Thu, 11 Aug 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/achieving-the-gold-standards-of-organ-modelling-complexity-robustness-and-reproducibility We hear the opinions of organ modelling experts on navigating three concepts which are critical to the field: complexity, robustness, and reproducibility. Tue, 30 Aug 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/using-innovative-approaches-to-expand-the-druggable-genome Investigating the mysteries of proteins considered undruggable to expand the druggable genome. Thu, 08 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/delix-therapeutics-announces-2-partners-in-neuroscience-drug-discovery-effort The neuroscience discovery company alter the molecular chemistry of existing psychedelic drugs to maintain their psychoplastogenic properties but remove their hallucinogenic effects. Fri, 09 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/drugging-the-undruggable-targeted-protein-degradation Using the body's mechanisms to degrade proteins not amenable to traditional small molecule approaches, offering the potential to "drug the undruggable" and permanently destroy target proteins. Fri, 09 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/oracles-cerner-enviza-and-fda-collaborate-on-nlp-ai-drug-safety-tools The oracle company will partner with the FDA and John Snow Labs to develop natural language processing backed up by AI to study drug safety. Fri, 09 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/new-study-includes-pain-nvns-device-for-chronic-symptoms-of-nfl-players The study will focus on non-invasive vagus nerve stimulation (nVNS) and cannabidiol (CBD) as potential treatments. Thu, 15 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/the-highs-and-lows-of-applying-ai-to-drug-design September's discussion group takes us through AI applied to drug design. Where it has been useful, and where it has been not so useful. Tue, 27 Sep 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/alphafold-momentary-or-revolutionary AlphaFold, using AI/ML to predict the structures of proteins, has jumped off the pages of sci-fi and landed into the labs of researchers… but is it any good? Thu, 06 Oct 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/bicycle-therapeutics-publishes-preclinical-data-from-nectin-4-targeting-cancer-drug A paper published in the Journal of Medicinal Chemistry highlights Cambridge, UK based biotech, Bicycle Therapeutics' findings regarding bicycle toxin conjugate, BT8009. Tue, 11 Oct 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/orion-granted-e10m-to-build-ai-based-research-ecosystem-in-finland A Finnish government agency has awarded the pharma company €?10 million to invest in their research ecosystem utilising AI and data science. Wed, 19 Oct 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/alphabets-calico-and-terray-tx-announce-partnership-to-tackle-age-related-disease A partnership between computational drug discovery company Terray and Alphabet's Calico will focus on new therapies to fight age related disease. Thu, 27 Oct 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/1-2m-quantum-computing-drug-discovery-grant-secured-by-penn-state-researchers The grant will help researchers tackle diseases like cancer using quantum computing drug discovery Wed, 02 Nov 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/protein-linked-to-increased-nsclc-lung-cancer-survival Evidence shows that targeting TLR2 with an agonist reduces lung tumour growth in mouse models. Wed, 09 Nov 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/top-3-must-see-presentations-discovery-us-2022 Find out what you can't miss at Discovery US: In Person 2022... Wed, 16 Nov 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/small-molecule-targets-toxic-rna-linked-to-als-and-dementia A UF Scripps Biomedical Research team have developed an RNA-targeting blood-brain penetrant small molecule to tackle genetic cases of ALS and dementia. Wed, 23 Nov 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/alzheimers-drug-lecanemab-slows-cognitive-decline-at-cost-of-side-effects-shows-clinical-trial Eisai and Biogen have shared the data from a phase III trial of their joint effort Alzheimer's drug, lecanemab Wed, 30 Nov 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/accelerating-target-discovery-with-genomic-and-crispr-techniques Benedict Cross, Chief Technology Officer at PhoreMost, leads our Discussion Group on Target-Based Drug Discovery using Genomic and CRISPR techniques. Mon, 05 Dec 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/university-of-minnesota-awarded-6-5m-for-male-oral-contraception-discovery-effort The grant could open the door to new oral contraceptive medication for men and prevent unwanted pregnancy. Thu, 08 Dec 2022 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/addressing-specific-targets-and-dealing-with-target-engagement The panel discussion from Discovery US 2022, investigates into new technologies for target engagement and expanding the chemical space. Wed, 11 Jan 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/discovery-of-fentanyl-vaccine-called-game-changer-with-some-sceptical The antibody-based vaccine has been successful in rat models but has had critics who would rather see a focus on harm reduction. Fri, 13 Jan 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/positive-results-achieved-from-phase-iii-trial-of-mdma-assisted-therapy Significant findings after the Schedule I controlled drug completes Phase III clinical trial for PTSD patients. Thu, 19 Jan 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/gene-discovered-to-drive-anxiety-could-prove-an-effective-drug-target The discovery could be a game-changer for the many people that suffer from anxiety related mental health disorders. Mon, 23 Jan 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/automated-chemical-synthesis-experts-discuss-new-platform Our Discussion Group featured expert conversation on automation and synthesis from software to hardware, key challenges, and end goals. Thu, 26 Jan 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-valentina-mosienko-fellow-and-lecturer-in-neuroscience-university-of-bristol Navigating the neuroscientific pathways for anxiety towards druggable targets. Tue, 21 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-nicolas-vachicouras-ceo-neurosoft-bioelectronics-subdural-brain-interfaces Talking with Nicolas Vachicouras, CEO of Neurosoft Bioelectronics about their subdural brain interface and its inaugural clinical testing for recording the human brain in the context of an epilepsy resective surgery. Thu, 23 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-felix-hausch-professor-for-structure-based-drug-research-at-tu-darmstadt Felix will deliver his presentation 'Clues for Molecular Glues' at Drug Discovery Europe 2023. Tue, 28 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/using-ml-with-del-philogen-and-google-partner-in-new-study The partnership has developed a new machine learning assisted-technique for DEL screening. Tue, 28 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/using-breakthrough-computational-tools-for-drug-design-and-discovery-ai-ml-and-quantum-computing How quantum annealers, which use quantum mechanics to solve optimisation problems by finding the lowest energy state of a system, are being used for drug discovery. Wed, 29 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-thierry-dorval-head-of-data-sciences-data-management-at-servier Thierry Dorval from Servier talks about AI methods, their limitations, and how they are changing the way that data is viewed in the pharmaceutical industry. Thu, 30 Mar 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/first-paediatric-patients-enrolled-in-phase-iii-clinical-trial-for-leniolisib-rare-genetic-disease A clinical trial for the drug leniolisib will go ahead in studying paediatric patients with the rare genetic disease ADPS. Tue, 11 Apr 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/how-del-screening-is-used-in-living-cells Living cells create a more relevant physiological environment for DEL screening, says Dr Iolanda Micco, Associate Director of Chemistry & Alliances at Vipergen Wed, 19 Apr 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/nasal-spray-shows-remarkable-efficacy-in-easing-social-anxiety-vistagens-fasedienol-promises-new-hope Positive phase III results propel innovative pherine nasal spray as potential game-changer for millions struggling with social anxiety disorder. Vistagen's novel mechanism of action sparks optimism after previous setback. Tue, 02 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/cerebral-organoids-the-sci-fi-organ-model-explaining-our-brains These miniature brain replicas, cultivated from patient-derived stem cells, provide a unique window into the intricacies of brain development. Tue, 09 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/rna-interference-looking-back-at-the-2006-nobel-prize Fire and Mello's research has unlocked a powerful new therapeutic technology: silencing genes with siRNA. Tue, 09 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-jissy-akkarapattiakal-kuriappan-principal-investigator-drug-discovery-at-alembic-pharmaceuticals Jissy Akkarapattiakal Kuriappan, Principal Investigator, Drug Discovery at Alembic Pharmaceuticals, discusses using AI to promote drug discovery, the problem with using AI as a black box, and whether AI and ML are a worthwhile investment. Fri, 12 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/potential-antidote-discovered-for-centuries-old-toxic-mushroom Researchers have discovered a potential antidote, indocyanine green (ICG), for the highly toxic death cap mushroom, Amanita phalloides. Thu, 18 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/investigating-target-identification-and-validation-modelling-in-neurodegenerative-disease The significance of reproducibility, fidelity, and translatability in models, as well as the importance of using multiple models to cross-validate therapeutic targets. Fri, 26 May 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/university-of-sydney-enters-new-drug-discovery-ai-partnership-with-pharos-tx The collaboration involves granting the university access to Pharos' proprietary AI platform, Chemiverse, while Pharos will collaborate with the university's drug discovery researchers and infrastructure. Mon, 05 Jun 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/addressing-the-challenges-of-cell-models-in-research-and-drug-discovery The complexities of developing cell models and testing novel therapies: considering throughput, consistency, and reproducibility. Fri, 09 Jun 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/leading-perspectives-on-using-ai-tools-to-drive-drug-design Our expert panel discuss the implementation of AI and ML tools for drug design: predictive models, computational chemistry, and AlphaFold. Mon, 12 Jun 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/interview-with-yusuke-tominari-co-founder-and-ceo-of-fimecs Yusuke will be giving a keynote presentation at Discovery Europe 2023 titled 'Targeted Protein Degradation And Addressing Undruggable Targets'. Mon, 03 Jul 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/scientists-create-transparent-mouse-to-advance-preclinical-medicine The method, known as tissue clearing and immunolabeling, enables the detection of tumours at the single-cell level. Tue, 11 Jul 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/what-is-alphafold-protein-folding-problem AlphaFold is the protein folding solution that took computational biology by storm, but has the protein folding problem been well and truly solved? Tue, 11 Jul 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/prothena-and-evotec-score-major-deals-with-bristol-myers-squibb-for-neuroscience-breakthroughs Prothena will receive $55 million to license its clinical Alzheimer's drug candidate, while Evotec will receive $40 million for its late-stage clinical programs. Fri, 14 Jul 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/challenges-in-developing-organoids-for-neuroscience Oxford Global's panel discussion: Translational Models from 3D to Animal Model of Disease – Neuroscience, asked experts to share their experience of developing organoids for translational neuroscience. Tue, 01 Aug 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/navigating-del-screening-from-hit-to-lead The panel at Drug Discovery US discussed hit finding technologies, protein availability for screening, and hit-to-lead transition. Tue, 08 Aug 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/experts-discuss-next-generation-organoids-challenges-and-the-future How do scientists secure the tissue they need? Should scientists be careful with the words they use for next generation technologies? And why is validation for organ modelling so important? Thu, 14 Sep 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/challenges-and-opportunities-in-targeted-protein-degradation-current-and-future-strategies Discussing the challenges and strategies in targeted protein degradation (TPD), a promising therapeutic modality with the potential to drug difficult or "undruggable" protein targets. Mon, 25 Sep 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/biophysical-tools-for-the-design-and-development-of-protacs Protein degradation has emerged as a promising new field of therapeutics. What are biophysical tools are employed for the characterisation of these drugs? Thu, 19 Oct 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/vascular-organoids-used-to-model-the-impact-of-covid-19-on-circulation Researchers have used vascular organoids to look at the impact of SARS-CoV-2 on blood circulation, which has led to the discovery of a potential therapeutic target. Thu, 26 Oct 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/pivot-park-screening-centre-we-help-you-to-accelerate-drug-discovery Are you looking for lead candidate compounds for your target or cellular phenotype, and do you want your drug discovery program to be more efficient, both in terms of time and cost? Thu, 16 Nov 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/talking-protein-degraders-with-benedict-cross-cto-and-head-of-platform-at-phoremost Delving into PhoreMost's role in targeted protein degradation, the innovation behind the SITESEEKER platform, and the challenges and breakthroughs in the dynamic field of drug discovery. Wed, 22 Nov 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/spheroids-assembloids-could-unlock-high-throughput-screening-of-neuro-drugs These spheroids can mimic different sections of the human brain based on their cell-type composition, and promisingly could enable high-throughput screening of neurology drugs. Wed, 29 Nov 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/targeting-novel-e3-ubiquitin-ligases-carles-galdeano-professor-university-ofbarcelona We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics. Fri, 01 Dec 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome The collaboration hopes to develop a AAV gene therapy for rare genetic disease Angelman syndrome. Tue, 12 Dec 2023 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/bruker-corp-to-buy-chemspeed-in-ramp-up-of-automation-portfolio Automation of laboratory workflows can improve the speed and efficiency of QC and R&D; the acquisition represents the development of Bruker's entry into the field. Mon, 29 Jan 2024 13:00:00 GMT discovery http://www.oxfordglobal.com/discovery-development/resources/stability-can-be-a-problem-dealing-with-nanoparticle-stability-challenges-in-drug-formulation Cholesterol oxidation, working with regulators, drug loading nanoparticles, and functional excipients for specific pathways. Tue, 21 Mar 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/a-look-at-new-process-development-techniques How do we make the most of new techniques to optimise product development? Mon, 14 Feb 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/advanced-formulation-development-strategies-towards-sustainable-lyophilisation Optimising drug delivery, stability, and patient outcomes through considerations such as formulation simplicity, critical temperatures, excipient selection, and the use of digital approaches. Wed, 24 May 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/bath-university-develops-microneedle-skin-patch-for-painless-drug-delivery The microneedle drug delivery skin patch is made of hydrogel, making it cheap and sustainable to produce. Tue, 21 Nov 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/celadons-medicinal-cannabis-facility-awarded-gmp-registration-by-mhra The medicinal cannabis manufacturer Celadon Pharmaceuticals has had its facility in the Midlands registered as GMP by MHRA. Thu, 19 Jan 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/challenges-in-the-formulation-of-biologics-protein-aggregation-safety-and-technology Our panel discussion from Formulation UK 2021 highlights protein aggregation, safety, and novel technologies. Fri, 07 Oct 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/cipla-stock-falls-after-8-observations-from-gmp-inspection The Indian pharma giant comes out of inspection with eight observations in its generic manufacturing plant. Mon, 20 Feb 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/controlled-drug-delivery-of-oral-liquid-dosage-forms Liquid formulations of medicines exist to serve the needs of vulnerable patients. What are their applications? And what challenges are they facing, both in industry and on the market? Thu, 17 Nov 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/cros-strategy-and-sustainable-testing-navigating-formulation-development-for-biologics An expert panel of formulation scientists discuss the challenges and solutions within the formulation development for biologics. Mon, 16 Jan 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/examining-new-technologies-for-therapeutic-delivery Our discussion group on new delivery technologies considered novel and imaginative techniques for delivering drugs to their active sites. Wed, 04 Jan 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/experts-discuss-the-particular-challenges-of-biotherapeutic-formulation-development Our Formulation discussion group this September focused on the unique challenges of developing formulations for biotherapeutics Mon, 10 Oct 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/experts-investigate-the-process-and-formulation-of-dry-powder-inhalers-drugs Our Inhaled Therapeutics discussion group brought together key experts in the field of dry powder formulation to discuss their research into both formulation and process. Wed, 09 Nov 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/exploring-ways-of-crossing-the-blood-brain-barrier The blood-brain barrier is one of the greatest challenges in drug delivery. The complex issue of getting active molecules out of the blood and into the brain is a task that requires innovative solutions. We discuss some of those methods here. Thu, 01 Sep 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/fda-publishes-paper-asking-manufacturers-for-feedback-on-ai-and-regulation Key regulatory considerations for the application of AI to pharmaceutical manufacturing were outlined by the Center for Drug Evaluation and Research. Fri, 31 Mar 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/from-lnps-to-aavs-overcoming-rna-delivery-challenges RNA therapeutics have great potential, as evidenced by the success of Pfizer-BioNTech and Moderna's COVID vaccines. One difficulty that may stunt their success lies in their delivery challenges. Thu, 08 Sep 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/inhaled-biologics-where-are-we-now Inhaled biologics are being evaluated as an alternative to injections for treating rare and serious diseases. Experts touch on several challenges including making stable and safe formulations of inhaled biologics. Thu, 13 Apr 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/kurma-partners-to-collaborate-with-samsung-biologics-for-the-development-and-manufacture-of-biologics-drugs Samsung Biologics will develop and manufacture drugs for Kurma's portfolio companies, including by providing CMC drug development. Tue, 24 Oct 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/merck-and-xtalpi-collab-for-computational-drug-development-techniques The study highlighted the benefits of combining computational workflows with experimental validation for the rational engineering of desirable crystal habits, demonstrating how the collaboration is transforming pharmaceutical development and positively impacting patients' lives. Tue, 25 Apr 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/nanoscale-3d-printing-unleashed-the-path-to-personalized-medicine-and-4d-innovation The sintering process in nanoscale 3D printing has paved the way for 4D printing, allowing devices printed in 3D to undergo transformational deformation in response to stimuli. Tue, 20 Jun 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/new-freeze-drying-technologies-pfizers-quest-for-sustainable-cooling Pfizer continues to explore even greener alternatives to traditional lyophilisation methods like air cooling in its pursuit of environmental sustainability. Wed, 13 Sep 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/new-hiv-drug-formulation-breakthrough-for-paediatric-applications While anti-retroviral therapies (ARTs) have transformed HIV from a death sentence into a manageable condition, paediatric applications of these therapies have remained limited. Tue, 08 Aug 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/novel-delivery-systems-oral-films-for-patient-centric-care The team is now working on commercializing the technology through their start-up PharLyfe+. Wed, 05 Jul 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/optimising-patient-centric-design-for-inhaled-products Our expert panel discuss the process of ensuring that inhalation devices are not burdensome to use. Mon, 31 Oct 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/overcoming-challenges-in-formulating-and-delivering-rna-therapeutics-insights-from-formulation-delivery-us What needs to be considered for RNA drug delivery? From the stability of LNPs, to proteins in the blood, to descant selection and packaging. Wed, 17 May 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/prominent-names-in-rna-delivery-discuss-whats-around-the-corner Beyond the blood–brain barrier, the pulmonary power of nebulisers, and RNA science in the post-COVID era Fri, 11 Feb 2022 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/rani-strengthens-partnership-with-celltrion-to-develop-adalimumab-humira-biosimilar The collaboration will focus on RT-105, an orally administered biosimilar for adalimumab, an anti-inflammatory monoclonal antibody used to treat autoimmune diseases. Tue, 06 Jun 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/serina-therapeutics-licences-small-molecule-continuous-delivery-technology-to-pfizer Serina Therapeutics licences their continuous drug delivery platform to Pfizer, which includes lipid nanoparticle delivery systems. Mon, 20 Nov 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/sir-david-jack-a-titan-of-inhaled-medicine One of the pioneers of inhaled therapies, David Jack discovered countless drugs to treat asthma and similar conditions. Thu, 18 May 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/spotlight-on-mrna-vaccines-made-but-not-defined-by-the-pandemic Where is the formulation and delivery of mRNA vaccines heading in the years after the pandemic? Tue, 25 Apr 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/the-woman-who-changed-the-course-of-the-pandemic-katalin-kariko-and-the-mrna-revolution Karikó's efforts and dedication have had a profound impact on the world, allowing us to navigate the pandemic with the help of mRNA vaccines. Fri, 07 Jul 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/toward-sustainable-pharmaceutical-packaging-solutions-for-drug-manufacturers In the quest for sustainable packaging solutions in the pharmaceutical industry, drug manufacturers are grappling with the need to reduce waste while maintaining the stringent requirements for medicine packaging. Mon, 16 Oct 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/vanguard-strategies-perspectives-on-developing-novel-pharma-technologies Novel technologies in drug development, including personalized medicine manufacturing, cyclic peptides, and continuous manufacturing methods. Wed, 13 Sep 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/what-is-spray-freeze-drying Unlocking the potential of spray freeze drying: Challenges and strategies for commercialization Thu, 28 Sep 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/discovery-development/resources/toward-the-next-generation-of-sustainable-inhalers Millions use inhalers to treat pulmonary conditions in the UK. What is their environmental impact, and how can they be improved for a sustainable future? Thu, 14 Dec 2023 13:00:00 GMT formulation http://www.oxfordglobal.com/nextgen-biomed/resources/are-genomic-technologies-the-key-to-unlock-precision-immunotherapies The power of the genome has enormous implications for immunotherapy Tue, 22 Feb 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/re-educating-the-immune-system-a-brave-new-world-in-immunology RevoloBio's autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what's around the corner for the field. Thu, 24 Mar 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/insights-in-autoimmunity-and-immunotherapy Experts discuss elusively successful therapies and the rising costs that come with new technologies. Wed, 30 Mar 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/three-leading-perspectives-on-biomarker-diagnostic-discovery-in-immuno-oncology Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology. Thu, 07 Apr 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/search-and-destroy-engineering-t-cells-to-find-and-kill-cancer Oxford Global's Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T. Fri, 08 Apr 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/better-io-clinical-trials-with-immunopet-imaging Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs' at Oxford Global's discussion group. Thu, 14 Apr 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/tackling-solid-tumours-in-immuno-oncology What's next for CAR T cell therapy? What's the best way to develop combination therapies for multi-modal efficacy? Fri, 20 May 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/treating-autoimmune-diseases-past-present-and-future Bringing together the experts to discuss the timeline of autoimmune disease therapeutics. Wed, 25 May 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/the-future-of-car-t-for-solid-tumours-antigen-discovery-persistence-and-fitness CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours. Thu, 23 Jun 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/microbiome-solutions-to-immuno-oncology-problems Investigating the role of the microbiota in checkpoint inhibitor response. Thu, 14 Jul 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/aav-gene-therapy-and-car-t-therapies-immunogenicity-and-immunoassay-development Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS Tue, 02 Aug 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/preclinical-strategies-for-combination-immunotherapies Oncology is almost always oriented towards simultaneous treatment options. We explore why as well as the approach's unique challenges. Tue, 30 Aug 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/immuno-oncology-investigations-the-nkg2d-pathway-diagnostic-biomarker-and-allogenic-car-ts Cell UK 2021 hosts experts in cell and immunotherapy working towards new diagnostic tools and therapies. Mon, 12 Sep 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/the-challenges-facing-antibody-drug-conjugates-for-immuno-oncology The targeted cancer therapy has made recent clinical and market breakthroughs, but what are the next hurdles for ADCs? Fri, 23 Sep 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/immunology-from-cancer-to-covid Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19. Tue, 18 Oct 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/expert-opinions-on-targeting-the-tumour-microenvironment-present-challenges-and-future-outlook The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME. Tue, 08 Nov 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/delivering-immuno-oncology-therapies-for-solid-tumours The panel at Immuno UK 2022 discuss the unique challenges that come with delivering immunotherapies to solid malignancies. Tue, 22 Nov 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/what-are-the-key-challenges-in-developing-bispecific-antibodies-for-cancer-immunotherapy Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project? Wed, 07 Dec 2022 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/experts-discuss-developing-oncolytic-virus-therapy Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field Tue, 03 Jan 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/approaches-to-combinational-immunotherapies-from-clinic-to-approval Our panel discussing combination therapeutics addresses challenges, modelling, and the importance of biomarkers. Tue, 17 Jan 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/new-funding-given-to-network-of-experimental-cancer-treatment-centres The ECMC network will enter new partnerships to increase the availability of clinical trials for cancer patients. Thu, 19 Jan 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/teon-tx-and-msd-partner-in-oral-io-clinical-trial Teon Tx and MSD will partner to study a combination of a new immune-modifier and existing anti-PD-1 immune checkpoint inhibitor. Mon, 23 Jan 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/ai-guided-personalised-cancer-vaccine-designated-fast-track-by-fda Evaxion Biotech uses AI to personalise cancer vaccines for patients' specific tumours. Tue, 24 Jan 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/therapy-in-the-spotlight-car-t-cell-therapy-significant-approvals-and-regulatory-concerns What are the regulatory considerations for CAR T cell therapy, and what's next for the approach? Thu, 16 Feb 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/sensei-bio-presents-preclinical-data-for-novel-antibody-therapeutic-for-solid-tumours Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic. Wed, 22 Feb 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/chipscreen-licences-eucure-biopharmas-keytruda-competitor-for-greater-china The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing. Tue, 28 Feb 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/improving-patient-response-through-effective-biomarker-development Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development. Fri, 10 Mar 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/novel-targets-and-studies-in-immunology-and-autoimmunity-antigen-specific-immunotherapy-and-therapeutic-chaperones Insights on antigen-specific immunotherapy and the immunomodulatory functions of therapeutic chaperones at Immuno UK 2022. Wed, 29 Mar 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/evaxion-biotech-announce-new-source-of-immunotherapeutic-targets-via-ai-platform ERVs have been strongly associated with overall survival in cancer patients. Evaxion hopes they can act as therapeutic targets for non-responsive immunotherapy patients. Wed, 29 Mar 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/nk-cell-therapies-and-their-promising-possibilities Considering the potential of natural killer (NK) cells as immunotherapies for cancer treatment and the various methods being utilised to overcome cancer cells' resistance to NK cells. Thu, 20 Apr 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/ai-used-to-detect-rare-autoimmune-eye-disease The AI model, called VGG16, analysed CT scans of the eyes of patients and achieved an accuracy of 94.27%. Mon, 24 Apr 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/antibody-therapies-to-get-boost-from-genmab-and-argenx-partnership-for-immunology-and-oncology The partnership aims to address unmet patient needs in the areas of immunology and cancer. Thu, 04 May 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/a-new-age-of-biomarker-technologies-understanding-identification-validation-of-io-biomarkers Developing and validating IO biomarkers present challenges, such as working with challenging sample types, interpreting sequencing data, and integrating new technologies into the clinic. Wed, 10 May 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/cancer-vaccines-analysing-the-resurgence Looking at the past, present, and future of cancer vaccines. What are the reasons for past failings? And what's the next step for their development? Thu, 11 May 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/monoclonal-antibodies-guided-missiles-in-the-battle-against-cancer-and-more Monoclonal antibodies (mAbs) have emerged as highly promising and versatile treatments for various diseases, particularly cancer. Thu, 25 May 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/t-cell-atlas-of-tumour-microenvironment-identifies-previously-unknown-cell-state The atlas provides valuable insights into T cell phenotypic states across various cancer types, paving the way for biomarker discovery and the development of improved therapeutic strategies. Tue, 30 May 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/astrazeneca-and-daiichi-sankyo-share-results-of-io-combination-therapy-in-ib-clinical-trial Preliminary results from phase Ib clinical trial, TROPION-Lung02, evaluating the antibody drug conjugate datopotamab deruxtecan in combination with pembrolizumab. Thu, 08 Jun 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/william-coley-the-father-of-cancer-immunotherapy-and-his-legacy Despite facing criticism in his time, his work laid the foundation for modern immuno-oncology and his legacy continues through the Cancer Research Institute. Tue, 20 Jun 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/transformative-partnership-ozette-technologies-and-umoja-biopharma-join-forces-for-preclinical-studies The collaboration aims to expand access to immunotherapies and advance the field of CAR T cell therapy. Wed, 21 Jun 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/immune-cell-types-their-opportunities-for-therapeutic-use-in-oncology An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies. Wed, 12 Jul 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/another-partnership-from-takeda-and-f-star-therapeutics-to-look-for-antibody-based-therapies The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star. Thu, 13 Jul 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/using-mouse-models-for-preclinical-immuno-oncology Unveiling advancements in preclinical immuno-oncology: Exploring humanized mouse models and human knock-in mice for targeted cancer therapies. Wed, 02 Aug 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/exploring-oncology-biomarkers-in-early-clinical-trials-and-precision-medicine-challenges-and-opportunities The importance of validating hypotheses, understanding the biology of cancer progression, and utilising biomarkers in early screening to stratify populations and improve clinical endpoints. Mon, 14 Aug 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/ibio-reports-antibody-hat-trick-in-its-in-vivo-io-programs Significant progress in iBio's in vivo preclinical programs with positive data from three antibody candidates: anti-EGFRvIII, CCR8, and TROP-2 x CD3. Thu, 17 Aug 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/nk-cell-therapies-development-application-and-challenges Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery. Tue, 22 Aug 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/spotlight-on-padmanee-sharma-conquering-cancer-through-resilience-and-innovation Highlighting the exceptional contributions of Padmanee Sharma, whose unyielding determination led her to become a renowned physician and immunologist, reshaping the landscape of cancer research. Thu, 24 Aug 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/european-commission-approves-genmabs-subcutaneous-bispecific-antibody-tepkinly The approval follows positive results from Genmab's 'Epcore' phase I/II clinical trial. Tue, 26 Sep 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/compugen-exploring-new-pathways-and-combinations-in-immunotherapy Looking at new pathways for ICIs and Compugen's triple pathway hypothesis may be paving the way for next-generation cancer immunotherapy. Mon, 09 Oct 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/enfortumab-vedotin-pembrolizumab-combo-beats-chemo-in-phase-iii-breakthrough The Phase III clinical trial, named EV-302/KEYNOTE-A39, has unveiled that immunotherapy can outperform chemo in urothelial bladder cancer for the first time. Mon, 23 Oct 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/bispecific-antibody-format-interview-with-laura-von-schantz-chief-technology-officer-alligator-biosciences Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format. Thu, 02 Nov 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/positive-phase-i-data-from-oncolytic-virotherapy-trial TILT-123, an oncolytic virotherapy, has shown promising results from a phase I clinical trial which treats solid tumours in patients that have exhausted other options. Tue, 07 Nov 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/immunostimulatory-oncolytic-viruses-interview-with-angelica-loskog-ceo-lokon-pharma Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more. Tue, 14 Nov 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/upenn-medicine-presents-promising-phase-icar-t-trial-with-novel-binding-mechanism The CAR T therapy targets CD19 closer to the cell membrane and has demonstrated remarkable efficacy in its Phase I clinical trial. Tue, 12 Dec 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/experiments-link-gut-microbiome-and-graft-versus-host-disease Modulating the gut microbiome may be a key to preventing GvHD and stopping relapse. Mon, 22 Jan 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/new-multi-omic-ai-driven-initiative-for-immuno-oncology-biomarker-development The team aims to establish a consortium of cancer centres to join the project of developing biomarkers from multi-omic analysis. Thu, 29 Feb 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/in-vivo-models-show-survival-promise-for-zika-oncolytic-viral-therapy One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus. Wed, 06 Mar 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/zika-virus-tested-as-an-effective-oncolytic-agent-for-glioblastoma-in-in-vitro-models More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro. Tue, 19 Mar 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/positive-results-from-inkt-cell-therapy-clinical-trial-for-covid-19-ards The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19. Tue, 09 Apr 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/first-patient-dosed-with-nk-cell-therapy-for-the-treatment-of-an-autoimmune-disease-lupus-nephritis The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion. Tue, 23 Apr 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/patients-enter-clinic-for-phase-iii-mrna-immunotherapy-for-high-risk-melanoma The trial will test the world's first mRNA-based personalised immunotherapy for melanoma. Thu, 02 May 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/finding-new-immunotherapy-targets-for-solid-brain-tumour-car-ts-with-rnaseq-in-cancer-specific-exons The project has found over 150 target candidates for solid brain tumour therapies. Wed, 15 May 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/ai-enabled-predictive-biomarker-for-patient-response-to-immunotherapy-using-easy-to-measure-features The predictive biomarker does not require multi-omic or screening data, but rather routine clinical features. Mon, 10 Jun 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/strengthening-preparedness-for-the-next-pandemic-interview-with-ramin-sabet-azad-cmc-lead-cepi How do we prepare for the next pandemic? Thu, 26 Oct 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/vaccine-production-for-better-global-access How were the COVID-19 vaccines developed so fast? And why were some countries left behind? Wed, 11 Oct 2023 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/worlds-first-ind-approval-for-epstein-barr-mrna-cancer-vaccine Epstein-Barr virus has been highly linked to over ten forms of cancer. This wide range of malignant implications means an expanded variety of target indications for the vaccine. Tue, 14 May 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/h5n1-bird-flu-outbreaks-effect-on-vaccines H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines. Tue, 28 May 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/nhs-cancer-vaccine-launchpad-to-give-thousands-access-to-personalised-cancer-vaccines NHS England aims to match up to 10,000 cancer patients to suitable personalised cancer vaccine clinical trials by 2030. Mon, 17 Jun 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/scientists-develop-first-mouse-model-with-complete-functional-human-immune-system The breakthrough in mouse models will allow researchers to study the human immune system in far greater detail at a far greater pace. Wed, 10 Jul 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/car-t-beyond-cancer-applying-the-cell-therapy-for-lupus-and-other-autoimmune-diseases Can CAR T, which has had successes in immuno-oncology, be applied to reset the immune system of autoimmune disease patients? Tue, 30 Jul 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/msd-to-acquire-bispecific-antibody-from-curon-in-bid-to-diversify-portfolio The novel investigational clinical stage bispecific antibody targets CD3xCD19 to engage T cells with malignant B cells. Thu, 15 Aug 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/nextgen-biomed/resources/regenerons-bispecific-gets-eu-approval-after-fda-rejection The approval means that the bispecific antibody odronextamab can be used to treat adult patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the EU. Thu, 29 Aug 2024 13:00:00 GMT immuno http://www.oxfordglobal.com/precision-medicine/resources/using-ddpcr-to-assess-gene-editing-therapies When gene therapy goes wrong, it can have severe consequences. Dr Giandomenico Turchiano tells us how he can use ddPCR to catch those mistakes Mon, 31 Jan 2022 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/showcasing-bleeding-edge-genome-editing-companies-nextgen-omics-us Gábor Balázsi, Henry Laufer Professor of Physical and Quantitative Biology at Stony Brook University, takes us through the most valuable features that NextGen Omics US brought us in 2022. Wed, 18 May 2022 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/omics-us-2022-the-epicentre-of-the-spatial-omic-conversation Showcasing the highlights from NextGen Omics: In-Person 2022. We asked Alex Tamburino, Associate Principal Scientist at Merck about his experience at the event. Tue, 24 May 2022 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/10x-genomics-and-single-cell-rna-sequencing-interview-with-philip-bischoff-and-angela-churchill Unlocking the potential for FFPE samples in advancing single-cell sequencing for tumour microenvironment research. Fri, 06 Oct 2023 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/interview-with-gabriela-kramer-marek-associate-professor-reader-in-molecular-imaging-at-the-icr Talking patient stratification for immunotherapies and imaging agents, investigating PD-L1, and the work of the ICR. Fri, 02 Feb 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/spatial-and-single-cell-transcriptomics-uncovers-mechanisms-for-ischemic-stroke-recovery A team at Southeast University in Nanjing, China have investigated mouse models of ischemic stroke cases. Thu, 08 Feb 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/curio-bioscience-pen-partnership-with-dnanexus-simplifying-data-analysis-in-spatial-transcriptomics The partnership will allow Curio to give access to DNAnexus's bioinformatics platform to some of their customers. Thu, 22 Feb 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/research-spotlight-multi-omics-data-harmonization-for-sars-cov-2-virus-and-drug-target-identification The approach to omic data analysis combines multiple types of omic datasets in the hope of understanding multiple layers of a biological system. Wed, 13 Mar 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/roadblocks-to-the-sharing-of-large-multi-omics-datasets More analysis means more data, and sharing multi-omics datasets can present challenges as well as blessings. Mon, 18 Mar 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/pianno-a-model-for-the-annotation-of-spatial-transcriptomics-data The model has unveiled insights on the evolution and diversification of the cell types of the brain. Mon, 15 Apr 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/liquid-biopsy-for-early-stage-pancreatic-cancer-data-presented-at-aacr Earlier detection of pancreatic cancer could increase five year survival from 3% to 44%. Wed, 22 May 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/fda-advisors-back-guardants-colorectal-cancer-blood-test Although colonoscopy is definitively the most effective method of colorectal cancer diagnosis, the blood test is "better than nothing." Sun, 02 Jun 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/functional-genomics-reveals-major-cause-of-inflammatory-bowel-disease-discovered-by-uk-scientists Genomics helped the UK-based team track down a gene that, when over expressed, was significantly responsible for causing IBD. Wed, 05 Jun 2024 13:00:00 GMT omics http://www.oxfordglobal.com/precision-medicine/resources/investigating-a-novel-bacterial-form-for-biological-computers A novel method of computational biology using colonies of bacteria has been developed by researchers at University College London. Tue, 18 Jun 2024 13:00:00 GMT omics